3-PPP
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H21NO |
| Molar mass | 219.328 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-(1-Propyl-3-piperidinyl)phenol (3-PPP) is a mixed sigma σ1 and σ2 receptor agonist (with similar affinity for both subtypes) and D2 receptor partial agonist which is used in scientific research.[1][2] It shows stereoselectivity in its pharmacodynamics.[1] (+)-3-PPP is the enantiomer that acts as an agonist of the sigma receptors;[2] it is also an agonist of both D2 presynaptic and postsynaptic receptors.[1] Conversely, (–)-3-PPP, also known as preclamol (INN), acts as an agonist of presynaptic D2 receptors but as an antagonist of postsynaptic D2 receptors, and has antipsychotic effects.[1][3]
See also
References
- ^ a b c d Hjorth S, Carlsson A, Clark D, Svensson K, Wikström H, Sanchez D, Lindberg P, Hacksell U, Arvidsson LE, Johansson A (1983). "Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP". Psychopharmacology (Berl.). 81 (2): 89–99. PMID 6415751.
- ^ a b Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD (1994). "Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling". Eur. J. Pharmacol. 268 (1): 9–18. PMID 7925616.
- ^ Jeffrey S. Albert (6 June 2012). Targets and Emerging Therapies for Schizophrenia. John Wiley & Sons. pp. 64–. ISBN 978-1-118-30940-7.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |